Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling
暂无分享,去创建一个
F. Zhan | B. Barlogie | J. Shaughnessy | E. Anaissie | G. Tricot | J. Haessler | M. Zangari | J. Epstein | F. van Rhee | K. Hollmig | A. Mohiuddin | M. Pineda‐Roman | Y. Alsayed | J. Crowley | A. Hoering
[1] B. Barlogie,et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. , 2007, Blood.
[2] B. Barlogie,et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] B. Barlogie,et al. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease , 2007, British journal of haematology.
[4] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[5] David R Williams,et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. , 2006, Blood.
[6] B. Barlogie,et al. Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM). , 2006 .
[7] N. Schmitz,et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. , 2006, Blood.
[8] John Crowley,et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. , 2006, Blood.
[9] John Crowley,et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. , 2006, The New England journal of medicine.
[10] B. Barlogie,et al. Cure of myeloma: hype or reality? , 2005, Bone Marrow Transplantation.
[11] J. Crowley,et al. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Bataille,et al. Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.
[13] F. Zhan,et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. , 2003, Blood.
[14] John Crowley,et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.
[15] B. Barlogie,et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. , 2000, Blood.
[16] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[17] B. Barlogie,et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. , 1999, Blood.
[18] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[19] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[20] B. Barlogie,et al. Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.
[21] C. Coltman,et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma , 1976, Cancer.
[22] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .